Table 26.
Four-component synthesis of coumarin-substituted pyrazoles 93, 94, and 95 and their in vitro antibacterial activity (MIC) against four bacterial strains.
| |||||||
|---|---|---|---|---|---|---|---|
| Compound | R | R1 | Yield of 93, 94 and 95 (%) | Antibacterial Activity of Compounds 93, 94 and 95 (Minimum Inhibitory Concentration in μg/mL (MIC)) | |||
| SA | SF | EC | PA | ||||
| 93a | 6-Me | CN | 94 | 6.25 | 12.5 | 12.5 | 12.5 |
| 93b | 6-OMe | CN | 91 | 3.125 | 12.5 | 6.25 | 1.56 |
| 93c | 6-Cl | CN | 89 | 3.125 | 6.25 | 3.125 | 12.5 |
| 93d | 7-Me | CN | 92 | 6.25 | 12.5 | 0.78 | 3.125 |
| 93e | 7,8-Benzo | CN | 90 | 6.25 | 12.5 | 25.0 | 25.0 |
| 93f | 6-Me | CO2Et | 92 | 3.125 | 6.25 | 12.5 | 6.25 |
| 93g | 6-OMe | CO2Et | 89 | 1.56 | 3.125 | 6.25 | 6.25 |
| 93h | 6-Cl | CO2Et | 86 | 3.125 | 12.5 | 6.25 | 50.0 |
| 93i | 7-Me | CO2Et | 91 | 3.125 | 25.0 | 3.125 | 12.5 |
| 93j | 7,8-Benzo | CO2Et | 88 | 3.125 | 12.5 | 6.25 | 6.25 |
| 94a | 6-Me | -- | 89 | 3.125 | 12.5 | 12.5 | 25.0 |
| 94b | 6-OMe | -- | 80 | 0.78 | 1.56 | 3.125 | 6.25 |
| 94c | 6-Cl | -- | 77 | 1.56 | 6.25 | 25.0 | 50.0 |
| 94d | 7-Me | -- | 82 | 3.125 | 6.25 | 6.25 | 12.5 |
| 94e | 7,8-Benzo | -- | 89 | 6.25 | 12.5 | 6.25 | 12.5 |
| 95a | 6-Me | -- | 85 | 6.25 | 12.5 | 3.125 | 12.5 |
| 95b | 6-OMe | -- | 82 | 3.125 | 6.25 | 6.25 | 6.25 |
| 95c | 6-Cl | -- | 81 | 6.25 | 12.5 | 6.25 | 12.5 |
| 95d | 7-Me | -- | 84 | 6.25 | 6.25 | 12.5 | 6.25 |
| 95e | 7,8-Benzo | -- | 83 | 12.5 | 12.5 | 12.5 | 6.25 |
| Ciprofloxacin a | -- | -- | -- | 6.25 | 6.25 | 3.125 | 6.25 |
SA (Staphylococcus aureus), SF (Staphylococcus faecalis), EC (Escherichia coli), PA (Pseudomonas aeruginosa). a Standard drug for the study.